Shenyang Northern Hospital
42
3
4
19
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 25/100
2.4%
1 terminated/withdrawn out of 42 trials
95.0%
+8.5% vs industry average
50%
21 trials in Phase 3/4
0%
0 of 19 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (42)
Circumferential Pulmonary Venous Isolation Combined With Bachmann Bundle Modification Versus Circumferential Pulmonary Venous Isolation for Persistent Atrial Fibrillation
Role: lead
Bivalirudin Versus Heparin During PCI in High Bleeding Risk Patients With Acute Coronary Syndromes
Role: lead
Safety and Efficacy of De-escalation Dual Antiplatelet Therapy After BioFreedom™ Stenting in ACS Patients With Moderate-to-high Ischemic and High Bleeding Risk
Role: lead
Effect of Colchicine on Progression of Coronary Atherosclerosis in Patients With TET2-CHIP Variant
Role: lead
Optimization and Validation of Quality Control Indicators for Coronary Revascularization Based on Antiplatelet Therapy
Role: lead
CCTA Evaluation of SGLT2i-related Pericoronary Fat Changes in Non-diabetic ACS Patients Without HF
Role: lead
Safety and Efficacy of Pulmonary Artery Denervation in Patients With Pulmonary Arterial Hypertension
Role: collaborator
Early Thrombolysis Guided by AI-Assisted App in Patients With STEMI
Role: lead
Clinical Outcomes of Patients With Coronary Artery Disease
Role: lead
SGLT2-inhibitors on PC-AKI
Role: lead
CHIP and Residual Cardiovascular Event Tendency After Smoking Cessation
Role: lead
Effects of Yangxinshi Pills on the Exercise Tolerance Compared With Trimetazidine in Patients After PCI
Role: lead
OPT-CAD Score GUIded Dual ANtiplatelet De-esCalation Time
Role: lead
Bivalirudin With Prolonged Full Dose Infusion Versus Heparin Alone During Emergency PCI
Role: lead
Optimal antiPlatelet Therapy for High Bleeding and Ischemic RISK Patients Trial
Role: lead
OCT or Angiography Guided De-escalation of DAPT
Role: lead
Neointimal Features in Patients With Restenosis of Calcified Lesions
Role: lead
Mono- Versus Dual antiPlatelet Therapy During 6-12 Months After New Generation Drug Eluting Stent Implantation
Role: lead
CHD Patient's Concern on Cardiac Rehabilitation
Role: lead
Baduanjin Sequential Therapy and Cardiac Function of AMI With Reduced EF After PCI
Role: lead